Prostate Cancer

Neal Shore, MD, presents data on the tolerability of and responses to darolutamide (DARO) as seen in the extended follow-up of the phase 3 ARAMIS trial of DARO treatment in men with high-risk, nonmetastatic, castration-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Neal Shore, MD, presents data on treatment preferences from the phase 2 ODENZA trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Eric Klein, MD, discusses the promise of VERU-111 in patients with metastatic CRPC and other research efforts that are generating excitement in the paradigm.

Neal D. Shore, MD, FACS, discusses the design of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Arun Azad, MBBS, PhD, FRACP, discusses the rationale that inspired the launch of the UpFrontPSMA trial, and highlights past and future research directions with 177Lu-PSMA-617 in the treatment of patients with prostate cancer.

Álvaro Juárez Soto, MD, discusses the efficacy of apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Eric Klein, MD, discusses the rationale to evaluate VERU-111 in metastatic castration-resistant prostate cancer.

Tanya Dorff, MD, discusses encouraging data from a study evaluating bright white light in older patients with prostate cancer and updates from the phase ARAMIS trial.

The FDA granted a breakthrough therapy designation to 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Álvaro Juárez Soto, MD, discusses the rationale for examining apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, as seen in the phase 3 TITAN study.

Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.

Christopher Pieczonka, MD, discusses the design of the phase 3 VERACITY trial studying VERU-111 in patients with metastatic castration-resistant prostate cancer.

A water vapor ablation therapy has been shown to be able to reach and treat all prostate regions and eradicate intermediate risk, grade group 2 prostate cancer with acceptable safety and tolerability.

Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

Mark Christopher Markowski, MD, PhD, discusses the safety and efficacy of VERU-111 in patients with metastatic castration-resistant prostate cancer.

Robert Dreicer, MD, discusses the goals of the phase 3 VERACITY trial with VERU-111 in patients with metastatic castration-resistant prostate cancer.

The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.

Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

The tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager HPN424 demonstrated antitumor activity and was well tolerated in patients with metastatic castration-resistant prostate cancer.

Darolutamide remained well tolerated with a highly favorable safety profile when combined with androgen deprivation therapy in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

177Lu-PSMA-617, a targeted radioligand therapy, plus standard of care induced approximately a 40% reduction in the risk of death vs SOC alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Jason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.